Coronary disease & ACSResearch article
Cardiac myosin-binding protein C in ST-elevation myocardial infarction
- Blood samples were obtained at 6 ± 2 hourly intervals for 24 hours (hrs) for measurement of hs-cTnI and cMyC concentrations in patients with reperfused acute STEMI
Authors' conclusion
cMyC is a quantitative biochemical biomarker of myocardial injury in reperfused STEMI. Further studies, using optimised high-sensitivity assays, are warranted to evaluate its potential as a novel biomarker after acute MI.
Study context
- Population
- Patients with reperfused acute STEMI3T LGE-CMR at ∼3-5 days 69 · 3T LGE-CMR at ∼4 months 65
- Comparison
- cMyC against hs-cTnI and LGE-CMR
Main finding
As reported in the abstract
Correlation of acute cMyC with acute and final MI size on LGE-CMR · 6-hrs post reperfusion
Acute cMyC at all timepoints significantly correlated with acute and final myocardial infarction (MI) size; most strongly at 6-hrs post reperfusion
r = 0.7
Further findings
Discrimination of acute microvascular obstruction (MVO) by cMyC · 6-, 12-, 18- and 24-hrs
- Significant discriminatory power; the 6-hr level had the highest discriminative power
Hs-cTnI vs cMyC
- Hs-cTnI correlated more strongly with acute and final MI size compared with cMyC
- Hs-cTnI had significantly higher discriminatory ability in identifying MVO at 12-, 18- and 24-hrs
Original publication
Cardiac myosin-binding protein C in ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. Published 25 March 2026. doi:10.1093/ehjacc/zuag032
Summarised from the published abstract; every number is checked against it